Drug firms would prioritize EU over smaller UK market post Brexit warns ABPI

By Gareth Macdonald

- Last updated on GMT

Image: iStock/jmiks
Image: iStock/jmiks

Related tags United kingdom

Drug companies will prioritize the EU over the UK in the event of Brexit according to the ABPI, which says members recognize the benefits of centralised licensing.

The Association of the British Pharmaceutical Industry (ABPI) called for the UK to remain part of the EU today. The industry group - which represents drug manufacturers - argued that a ‘yes’ vote would mean licensing of medicines in Wales, England and Scotland would have to be conducted by a local agency rather than the EMA.

CEO Mark Thompson said: “If we left the EU this would mean that the licensing of new medicines would have to be handled by a UK agency as well as a European agency.​ 

Our members have confirmed that the applications for UK license would come after the European license due to the smaller patient population in the UK​.”

The comments are in line with those made by other UK pharmaceutical industry organisations​ and current GSK CEO, Andrew Witty​.

More to follow...

Related news

Show more

Related product

Understanding the hidden value of quality

Understanding the hidden value of quality

Content provided by Thermo Fisher Scientific – Production Chemicals and Services | 16-Jan-2023 | White Paper

The raw material supply is too vital to leave to chance, and quality-related supply chain activities are cornerstones to your success.

Related suppliers

Follow us


View more